Please assess the completion status of the following clinical trial:

Trial Title: Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years old.~* Medical record documentation of recurrent CDI including a positive C. difficile test within 60 days prior to enrollment and either: a) at least two recurrences after a primary episode and has completed at least two rounds of standard-of-care oral antibiotic therapy or b) has had at least two episodes of severe CDI resulting in hospitalization.~* Documented history that the subject's recurrent CDI is controlled while on antibiotics even if the subject is not currently on antibiotics.~* A positive stool test for the presence of C. difficile within 60 days prior to enrollment~Exclusion Criteria:~* A known history of continued CDI diarrhea despite being on a course of antibiotics prescribed for CDI treatment.~* Requires continuous antibiotic therapy for a condition other than CDI.~* Previous successful (resolution of CDI diarrhea) fecal transplant for recurrent CDI \< 6 months prior to study enrollment.~* Previous unsuccessful (recurrent CDI diarrhea was unresolved) fecal transplant.~* Previous treatment with RBX2660.~* Diagnosis of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's disease, or microscopic colitis.~* Diagnosis of irritable bowel syndrome (IBS) as determined by Rome III criteria.~* History of chronic diarrhea.~* History of celiac disease.~* Disease symptoms caused by a confirmed intestinal pathogen other than C. difficile.~* Colostomy.~* Planned surgery requiring perioperative antibiotics within 3 months of study enrollment.~* Life expectancy of \< 12 months.~* Compromised immune system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RBX2660 Open-label (Type: EXPERIMENTAL): RBX2660 (microbiota suspension)
- Historical control antibiotics (Type: OTHER): Retrospective Historical Control with standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).